A detailed history of Epoch Investment Partners, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Epoch Investment Partners, Inc. holds 202,267 shares of SUPN stock, worth $5.27 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
202,267
Previous 346,336 41.6%
Holding current value
$5.27 Million
Previous $10 Million 31.16%
% of portfolio
0.03%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $3.91 Million - $5.07 Million
-144,069 Reduced 41.6%
202,267 $6.9 Million
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $938,722 - $1.23 Million
-41,317 Reduced 10.66%
346,336 $10 Million
Q3 2023

Nov 13, 2023

SELL
$27.57 - $32.91 $2.44 Million - $2.91 Million
-88,386 Reduced 18.57%
387,653 $10.7 Million
Q2 2023

Aug 11, 2023

BUY
$29.91 - $38.73 $36,370 - $47,095
1,216 Added 0.26%
476,039 $14.3 Million
Q1 2023

May 12, 2023

BUY
$34.93 - $42.03 $18,163 - $21,855
520 Added 0.11%
474,823 $17.2 Million
Q4 2022

Feb 13, 2023

SELL
$31.09 - $37.88 $526,571 - $641,573
-16,937 Reduced 3.45%
474,303 $16.9 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $437,579 - $538,196
15,199 Added 3.19%
491,240 $16.6 Million
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $483,144 - $653,284
-19,074 Reduced 3.85%
476,041 $13.8 Million
Q1 2022

May 13, 2022

BUY
$28.51 - $32.9 $1.05 Million - $1.22 Million
36,960 Added 8.07%
495,115 $16 Million
Q4 2021

Feb 11, 2022

BUY
$26.37 - $34.22 $1.81 Million - $2.35 Million
68,750 Added 17.66%
458,155 $13.4 Million
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $9.17 Million - $12.2 Million
389,405 New
389,405 $10.4 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.39B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Epoch Investment Partners, Inc. Portfolio

Follow Epoch Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Epoch Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Epoch Investment Partners, Inc. with notifications on news.